Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest SLE Stories

2010-06-18 14:03:02

The Chinese Systemic Lupus Erythematosus (SLE) Treatment and Research Group (CSTAR) announced interim epidemiological information on SLE patients in China today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Robust data on SLE patients has been scarce to date; but now CSTAR provides the first online registry of this magnitude in China. To date the registry has collated data from 2,104 SLE patients across 30 Chinese provinces. An initial...

00ddc11b86dc7eb02cafbc24e44457491
2010-06-18 09:10:00

Association between coffee consumption and RA not found Women who drink tea have an increased risk of developing rheumatoid arthritis (RA) compared with those who drink none (p=0.04), according to results presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Further results from the same study showed no correlation between the amount of coffee consumption and RA incidence (p=0.16). The results of the US based longitudinal cohort study...

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEM(TM), suggest promising results of epratuzumab in patients with SLE. EMBLEM(TM) was a 12-week,...

2010-06-15 07:00:00

EXTON, Pa., June 15 /PRNewswire/ -- BioTrends is pleased to announce the upcoming publication of a new syndicated report, TreatmentTrends®: Systemic Lupus Erythematosus (SLE). This report will provide a comprehensive market overview of current and future treatment trends in SLE based on a primary research study fielded with 102 rheumatologists in the U.S. during the first week in June. Preliminary findings indicate that despite the availability of multiple treatment...

2010-06-10 13:42:00

HAYWARD, Calif., June 10 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders, today announced it has updated its Lupus Scientific Advisory Board. A-623 is Anthera's Phase 2b compound being developed as a treatment for systemic lupus erythematosus (SLE). "Anthera is developing a promising therapeutic for Lupus, a condition in great need of...

2010-06-01 13:27:06

Paves way for safety testing of potential new use for asthma drug National Institutes of Health scientists have discovered that the activation of immune cells called basophils causes kidney damage in a mouse model of lupus nephritis. These findings and the team's associated research in humans may lead to new treatments for this serious disease, a severe form of systemic lupus erythematosus (SLE) that affects the kidneys and is difficult to treat. In earlier research, the team found that mice...

2010-02-25 09:57:45

Study finds SLE patients at risk for developing atherosclerosis A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for...

48742cd046eb2db71838312cf8b77092
2010-02-01 09:15:56

In the new Swedish-Finnish study, published in Nature Genetics, the researchers identified five loci that predispose to an SLE-related disease in Nova Scotia duck tolling retrievers. The study indicates that the homogeneity of strong genetic risk factors within dog breeds make dogs an excellent model in which to identify pathways involved in human complex diseases. The results of the study also open the door for further studies of specific T-cell activation pathways in human populations. The...

2009-11-03 13:22:02

MUHC researchers link smoking to skin problems in people with SLE As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the...

2009-07-30 09:45:38

Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs. Because morbidity and mortality related to influenza are increased in immunocompromised patients, it is recommended that patients with SLE get annual flu shots, which are safe and do not increase disease activity. Both antibody and cell-mediated responses are involved in the immune response...